Biogen
Idec BIIB announced new data analyses from year one of the
two-year, pivotal, Phase 3 ADVANCE study of PLEGRIDYTM (peginterferon
beta-1a). PLEGRIDY is an investigational subcutaneous injectable for
relapsing forms of multiple sclerosis (RMS), in which interferon beta-1a
is pegylated to prolong the molecule's exposure in the body and enable
the study of a less frequent dosing schedule. Clinical and MRI data from
the study demonstrated a reduction in relapses, disability progression
and the number of MS lesions when compared to placebo, and further
support the clinical efficacy profile of PLEGRIDY. These data will be
presented this week at the 29th Congress of the European
Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in